Dr Li Fei, a leading expert in germ stem cells microinjection technology

　　Recently, we heard good news from Henan Jufeel Technology Group, Jufeel and the world-renowned germ stem cell ERC technology team reached a consensus, it plans to spend the first phase of RMB 80 million to establish “Nobel Prize winner workstation and the key R&D center for germ stem cells” in the "Beidaihe life and health industry innovation demonstration zone new area", to promote the clinical transformation and application of biological cell technology. At present, Li Fei, main technical team leader of the project, global leader in germ stem cell technology, and the medical doctor of the People's Liberation Army General Hospital (301 Hospital), has represented the team to exchange views twice with seniors of Jufeel in the Beidaihe New Zone and the Zhengzhou Jufeel headquarters respectively and conducted in-depth communication on the cooperation framework.

　　Li Fei, Master of Clinical Medicine, Jilin University; Doctor of Nephrology, People's Liberation Army General Hospital (301 Hospital); guest Professor of Beihua University, fellow of Academician Chen Xiangmei. From 2000 to 2003, he worked in the nephrosis internal medicine department of 301 Hospital, engaged in clinical diagnosis and basic research in biotechnology, and later served as medical director of Hong Kong Pacific Medical Management Group. Currently, Li Fei is the chief medical technology officer of Beilian Meiou Biotechnology Co., Ltd., the executive director of the China Nobel Prize Winners Summit Forum Organizing Committee, the executive director of the Foreign Exchange and Technical Cooperation Department of the China Science and Technology Industry Association, and the executive director of the Technical Innovation and Application Branch of the China Anti-Aging Promoting Association.

　　Dr. Li Fei has been engaged in the research of biotechnology in the field of anti-aging since 2003. His main research direction is individual comprehensive rejuvenation and sexual health. The main research content is the mechanism of action of biological cells in the field of anti-aging and chronic disease management. He began to research the IMC series products from 2010, and participate in the research and application of genetic testing and biological immune cell therapy technology. His R&D results IMC active cell subcutaneous injection technology, ERC male donor stem cell microinjection technology has been successfully clinically transformed. And he created the biological diagnosis and treatment technology system with complete" intelligent micro-shaping "and" precise rejuvenation management ", and achieved the safety and efficacy beyond the traditional technology, which has been recognized by the medical community.

　　Jufeel has invested heavily this time, and its intention is very obvious, that is, to aim at the stem cells in the segment of the hot stem cell field. According to the agreement between the two parties, the key R&D center to be established will be settled in the second life and health industry innovation demonstration zone, Beidaihe life and health industry innovation demonstration zone new area, following the Hainan Boao Medical Tourism Pioneer Zone. The R&D center focuses on the R&D of the core technology system of “stem cell reproduction and anti-aging”. In addition to Dr. Li Fei, the core experts of the R&D Center include Richard J. Roberts, the winner of the 1993 Nobel Prize in Physiology or Medicine, an England biochemist and molecular biologist, and academician of the Royal Society; Dr. Lin Feng, former R&D director of Entest biomedical company, senior scientist of US Inovio Pharmaceutical Company (NYSE: INO), Doctor of medicine, Xiangya medical college, Central South University, and other international medical experts.

　　Jufeel said that it will jointly establish a limited company with the germ stem cell ERC technical team in Hong Kong soon, using the integration of capital and technology to rapidly promote the development of germ stem cell ERC precision medicine and biotherapy technology. Zhang Rongxuan, chairman of Jufeel Technology Group, said that in addition to the R&D direction of local injection technology for ERC vascular endothelial stem cells, it will also introduce the mature such as medical cold compress (mask), stem cell freeze-dried powder (coating preparation) and other high-end medical beauty products to the global market with the help of the mature sales system of Jufeel widespread in China, in order to achieve the financial profitability and market share of the company.

　　The international capital team involved in the negotiation also has Dr. MaxiBank (Victor Liu), the representative on behalf of Raffles Financial Limited, a word renowned financial institution. Dr. Victor Liu said that he is very optimistic about the cooperation between the two parties. Raffles will serve as the financial advisor and capital representative of the joint limited company, and responsible for incubating the project to connect with the capital market, striving to promote the RTO listing of the project in Hong Kong early next year based on the financial profitability of the project.